KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Receivables - Other (2018 - 2026)

Gilead Sciences filings provide 8 years of Receivables - Other readings, the most recent being $629.0 million for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 127.08% to $629.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $629.0 million, a 127.08% increase, with the full-year FY2025 number at $629.0 million, up 127.08% from a year prior.
  • Receivables - Other hit $629.0 million in Q4 2025 for Gilead Sciences, down from $695.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $695.0 million in Q3 2025 to a low of $117.0 million in Q4 2023.
  • Median Receivables - Other over the past 5 years was $169.0 million (2021), compared with a mean of $230.8 million.
  • Biggest five-year swings in Receivables - Other: crashed 31.58% in 2023 and later surged 277.72% in 2025.
  • Gilead Sciences' Receivables - Other stood at $174.0 million in 2021, then dropped by 1.72% to $171.0 million in 2022, then crashed by 31.58% to $117.0 million in 2023, then surged by 136.75% to $277.0 million in 2024, then soared by 127.08% to $629.0 million in 2025.
  • The last three reported values for Receivables - Other were $629.0 million (Q4 2025), $695.0 million (Q3 2025), and $305.0 million (Q2 2025) per Business Quant data.